Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Stabilized enzymes or enzymes complexed with nonenzyme (e.g., liposomes, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424940100 - ENZYME OR COENZYME CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110177053NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.07-21-2011
20110206652METHODS FOR TREATING ATHEROSCLEROSIS - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.08-25-2011
20110206651FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.08-25-2011
20120244137Method of Purifying Pegylated Proteins - The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.09-27-2012
20130084274Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z04-04-2013
20130084273Variant Form of Urate Oxidase and Use Thereof - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.04-04-2013
20130034533High Molecular Weight Derivatives of Vitamin K-Dependent Polypeptides - Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.02-07-2013
20120207735NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion to apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.08-16-2012
20130039897COMPOSITIONS AND METHODS FOR REGULATING NEUTROPHIL MOVEMENT AND NEUTROPHIL NUMBERS IN A BODY REGION - The disclosure relates to compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a 02-14-2013
20120263700HUMAN CYSTATHIONINE BETA-SYNTHASE VARIANTS AND METHODS OF PRODUCTION THEREOF - Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.10-18-2012
20100104547TOPICAL COMPOSITION FOR THE TREATMENT OF ALLERGENIC EFFECTS - A topical composition for treating stings and insect bites effectively significantly reducing pain and/or eliminating it (wiping away pain, or WAP) is disclosed comprising a stabilized proteonaise, antibacterial/anti-microbial, a cooling agent, an anti-inflammatory agent, a debriding agent and an exfoliating agent.04-29-2010
20130052176APTAMER FOR NGF AND USE THEREOF - Provided is a higher quality aptamer having a binding activity to NGF.02-28-2013
20110014173AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME - Disclosed are novel inhibitors of the AxI receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.01-20-2011
20090269323NON-AMPHIPHILE-BASED WATER-IN-WATER EMULSION AND USES THEREOF - The present invention relates to a non-amphiphile-based water-in-water emulsion composition. The non-amphiphile-based water-in-water emulsion composition includes a water-soluble polymer, a non-amphiphilic lyotropic mesogen encapsulated by the water-soluble polymer; and water. In one embodiment, the non-amphiphilic lyotropic mesogen includes, without limitation, a lyotropic chromonic liquid crystal, and more specifically disodium cromoglycate (DSCG). In another embodiment, the water-soluble polymer can include, without limitation, a polyacrylamide, a polyol, a polyvinylpyrrolidone, a polysaccharide, or a water-soluble fluoride-bearing polymer. The present invention also relates to a porous hydrogel made with the use of the non-amphiphile-based water-in-water emulsion. The present invention further relates to using the emulsion and hydrogel for various applications.10-29-2009
20090074739Pharmacological vitreolysis - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.03-19-2009
20120237491PHAGE DERIVED ANTIMICROBIAL ACTIVITIES - The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.09-20-2012
20130164273REVERSIBLY INACTIVATED ACIDIFIED PLASMIN COMPOSITION - The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.06-27-2013
20110086013ACYLGLYCEROL ACETYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF - The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.04-14-2011
20110027249Fusion of Peptidoglycan Hydrolase Enzymes to a Protein Transduction Domain Allows Eradication of both Extracellular and Intracellular Gram Positive Pathogens - Lysostaphin is a bacteriocin secreted by 02-03-2011
20100239554EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME - The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.09-23-2010
20110110912STORAGE-STABLE GLUCOSE OXIDASE - The present invention provides methods and compositions comprising at least one glucose oxidase enzyme, wherein the glucose oxidase has improved storage stability. In some preferred embodiments, the glucose oxidase enzyme is stable after exposure to elevated temperatures. In some alternative preferred embodiments, the glucose oxidase has improved storage stability in liquid formulations. In some particularly preferred embodiments, the present invention provides methods and compositions comprising glucose oxidase(s) obtained from 05-12-2011
20110286989ANGIOGENIN COMPLEXES (ANGex) WITH LIPID-BASED SUBSTRATES AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing stabilized angiogenin compositions by immobilization on a lipid-based substrate, such as a phospholipid or Coenzyme-Q10, are disclosed.11-24-2011
20110286988FVIII Muteins for Treatment of Von Willebrand Disease - This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking von Willebrand Factor.11-24-2011
20110293591Composition - The present invention provides a composition, and a process for preparing and method for using such a composition. The composition comprises (i) a surface coating material; and (ii) (ii) a cross-linked enzyme crystal or cross-linked enzyme aggregate wherein the enzyme is cross-linked with a multifunctional cross-linking agent and wherein the cross-linked enzyme crystal or cross-linked enzyme aggregate has an antifouling activity or generates an antifouling compound. Suitably the composition may be used to inhibit biofilm formation.12-01-2011
20110293590PHARMACEUTICAL PREPARATION - The pharmaceutical preparation for the treatment of pancreatic insufficiency comprises a liquid administering form of enzymes.12-01-2011
20110300120OLIGOSACCHARIDE-PROTEIN CONJUGATES - Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.12-08-2011
20110300121Stabilization Of Perhydrolases - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.12-08-2011
20090022702METHODS FOR INTRODUCING MANNOSE 6-PHOSPHATE AND OTHER OLIGOSACHARIDES ONTO GLYCOPROTEINS - Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose 6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.01-22-2009
20120189601ASSISTED ENZYME REPLACEMENT THERAPY - Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates.07-26-2012
20110044968COMPOSITIONS FOR TREATMENT WITH METALLOPEPTIDASES, METHODS OF MAKING AND USING THE SAME - The present invention is directed to biocompatible compositions and the use of metal bridges to connect a back-bone and a metallopeptidase active agent. In certain instances, the subject compositions provide a means of achieving sustained release of the metallopeptidase active agent after administration to a subject.02-24-2011
20100303787Methods of Treating Urogenital-Neurological Disorders Using Galanin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.12-02-2010
20110171191SUPPRESSION OF NEUROENDOCRINE DISEASES - The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptora melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion—from said tumourcell. The present invention also relates to polypeptides and nucleic acids for use in said methods.07-14-2011
20110171190PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.07-14-2011
20130216513Chimeric Clotting Factors - Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasia using these clotting factors.08-22-2013
20090169534Variant Forms of Urate Oxidase and Use Thereof - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.07-02-2009
20120294843CASPASE INHIBITORS - A compound, or a pharmaceutically acceptable salt or ester thereof, of formula I:11-22-2012
20100143321THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA - A therapeutic agent for interstitial pneumonia is provided which effectively exploits the effect of superoxide dismutase (SOD). The therapeutic composition for interstitial pneumonia contains 10 to 100 mg of lecithinized superoxide dismutase represented by the following general formula (I):06-10-2010
20090136474Stabilized Protease Composition - A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I:05-28-2009
20090081180ANTIMICROBIAL POLYMER CONJUGATES - Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions.03-26-2009
20110223147LYSOSOMAL TARGETING PEPTIDES AND USES THEREOF - The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.09-15-2011
20090208474BIOLOGICAL ENTITIES AND THE USE THEREOF - The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes.08-20-2009
20120171188Artificial Peptidoglycan Lysing Enzymes and Peptidoglycan Binding Proteins - The present invention relates to recombinant polypeptides having the activity of binding and lysing of bacteria, comprising at least one enzymatically active domain and at least two bacterial cell binding domains. The present invention further relates to recombinant polypeptide having the activity of binding bacteria, comprising at least two bacterial cell binding domain. Further the present inventions relates to nucleic acid molecules comprising a nucleotide sequence encoding the recombinant polypeptides, vectors and host cells.07-05-2012
20100254963PEG-MODIFIED ARGININE/LYSINE OXIDOREDUCTASE - The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol and to a production method thereof and to methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.10-07-2010
20100254964Modified Bouganin Proteins, Cytotoxins and Methods and Uses Thereof - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.10-07-2010
20120141450RISK MARKERS FOR CARDIOVASCULAR DISEASE - The invention relates to a method for determining the risk of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.06-07-2012
20120141449Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.06-07-2012
20120195872ANTIMICROBIAL AGENTS - The present invention relates to antimicrobial agents against Gram-positive bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-positive bacteria and an additional peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-positive bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-positive bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Further, the present invention relates to a pharmaceutical composition comprising said fusion protein.08-02-2012
20130129701Methods and Compositions for Sequence Specific RNA Endonucleases - The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.05-23-2013
20100303788Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions.12-02-2010
20100303789Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions.12-02-2010
20100303786Stabilisation of Liquid-Formulated Factor VII(A) Polypeptides by Aldehyde-Containing Compounds - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a R—CHO motif, e.g. Benzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, or 5-formyl-4-methylimidazole.12-02-2010
20100310540METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIA ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS - Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity, e.g. stabilized TAFIa, to ameliorate one or more adverse side effects of the therapeutic. Compounds identified by the methods of the invention are also provided.12-09-2010
20110110911Methods of Treating Cancer Using Tachykinin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.05-12-2011
20110243910 MAMMALIAN RNA DEPENDENT RNA POLYMERASE - The invention provides compositions comprising a TERT-RMRP or TERT-RNA complex and methods of treating subjects with genetic diseases in which gene silencing is either increased by administering the compositions of the invention or decreased by administering an inhibitor of the RNA-dependent RNA polymerase (RdRP) activity of these compositions. Moreover, the invention provides methods of screening for agonists and antagonists of RdRP activity and TERT-RMRP complex formation. Finally, the invention provides a method of identifying a RNA molecule that forms a complex with a TERT polypeptide and has RdRP activity.10-06-2011
20120244136Cardiac-Specific Protein Targeting Domain - The present invention relates to Cardiac Targeting Peptides or CTPs that are able to transduce cardiomyocytes specifically in culture and in vivo, and to methods for using such peptides and their derivatives to deliver peptides, proteins or nucleic acids specifically to the heart. It is based, at least in part, on the discovery that the peptide APWHLSSQYSRT (SEQ ID NO:1) functioned as a cardiac-specific protein targeting peptide and was successful in delivering a number of different cargoes to cardiac muscle cells in vitro and in vivo.09-27-2012
20100221234BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE - A bone delivery conjugate having a structure selected from the group consisting of: A) X-D09-02-2010
20110177052Stabilized Proteases For Use In Skin Care - Disclosed is an invention which relates to synthesizing immobilized and crosslinked proteases derived from plants for use as skin care agents. The resulting stabilized protease will minimally penetrate the skin because of its immobilized nature. It will retain activity because of its crosslinked nature and, in certain embodiments, due to its stabilization via physical additives. The present invention relates in particular to a linked papain product used in topical skin applications.07-21-2011
20110177051METHODS AND COMPOSITIONS FOR TREATMENT OF MITOCHONDRIAL DISORDERS - The present invention concerns in general novel fusion proteins comprising a membrane-transferring moiety and an enzymatic moiety. The present invention further concerns a method of treating disease using said fusion proteins.07-21-2011
20100047225OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.02-25-2010
20110165137SUPPRESSION OF CANCERS - The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.07-07-2011
20100330060GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.12-30-2010
20100330059CHIMERIC FACTOR VII MOLECULES - The present invention relates to chimeric Factor VII polypeptides and methods of using the same.12-30-2010
20120148558Delivery of Therapeutic Compounds to the Brain and Other Tissues - The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders.06-14-2012
20120148557ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS - The present invention relates to pharmaceutical preparations comprising albumin-fused coagulation factors for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders and to a method for increasing the in-vivo recovery after non-intravenous administration of a coagulation factor by fusing it to albumin.06-14-2012
20100322914PRODRUG ANTI-CANCER THERAPY - Compositions and methods for inhibiting the growth of cancer cells are provided. The cancer cells, the growth of which is inhibited, have constitutively active Abl tyrosine kinase activity due to a t(9;22)(q34;q11) translocation which results in expression of a chimeric Bcr-Abl protein which has constitutively active Abl tyrosine kinase activity that is believed to play an important role in leukemogenesis. The compositions include a modified protein kinase C(PKC) which has an Abl tyrosine kinase target motif. The methods involve administering the modified PCK to an individual to inhibit the growth of cancer cells that have Abl tyrosine kinase activity.12-23-2010
20100322913CHIMERIC POLYPEPTIDE COMPRISING THE FRAGMENT B OF SHIGA TOXIN AND PEPTIDES OF THERAPEUTIC INTEREST - The invention pertains to methods for using chimeric polypeptides of the formula:12-23-2010
20100158886Triple acting antimicrobials that are refractory to resistance development - Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live 06-24-2010
20120308544Substances and Methods for the Treatment of Lysosmal Storage Diseases - The present invention relates to a chimeric molecule comprising (i) a targeting moiety that binds to heparin or heparan sulfate proteoglycans, (ii) a lysosomal peptide or protein, (iii) wherein the targeting moiety is a neurotrophic growth factor and/or, wherein the targeting moiety comprises one of the following consensus sequences BBXB, BXBB, BBXXB, BXXBB, BBXXXB or BXXXBB and wherein B represents an arginine, lysine or histidine amino acid and X represents any amino acid, (iii) with the proviso that the targeting moiety is at least thirteen amino acids long.12-06-2012
20090175839PROTEINS WITH AN ATTACHED SHORT PEPTIDE OF ACIDIC AMINO ACIDS - Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with the native enzyme protein, the fusion protein exhibits higher transferability to bone tissues and improved, higher stability in the blood.07-09-2009
20110070215METHODS OF TREATING CANCER USING NEUROTROPHIN RETARGETED ENDOPEPTIDASES - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.03-24-2011
20110064714FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.03-17-2011
20110064713Methods of Treating Cancer Using Opioid Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.03-17-2011
20110318324METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.12-29-2011
20110318323METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.12-29-2011
20110318322Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer - Conjugates of a lysosomal enzyme moiety and one or more non-peptidic water soluble polymers are provided. Typically, the non-peptidic water soluble polymer is a poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising such conjugates, methods of making the conjugates, and methods of administering the compositions to a patient, e.g., for treatment of a lysosomal storage disease.12-29-2011
20110008309Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.01-13-2011
20120301455BOTULINUM TOXIN COMPOSITIONS - A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.11-29-2012
20120301453INHIBITING INTEGRIN RECEPTOR BINDING WITH NON-NATIVE MONOMERIC DISINTEGRIN OR MONOMERIC DISINTEGRIN DOMAINS - This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop.11-29-2012
20120003202CNS DELIVERY OF THERAPEUTIC AGENTS - The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.01-05-2012
20120014936METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.01-19-2012
20120009171METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.01-12-2012
20120058098NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.03-08-2012
20120207736COMPOSITION FOR CARTILAGINOUS TISSUE REPAIR AND A PRODUCTION METHOD THEREFOR - The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.08-16-2012
20120207734Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.08-16-2012
20120207733Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer or a disease of hyperproliferation in a mammal using such TVEMP compositions.08-16-2012
20120156186NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described.06-21-2012
20120207737MEDICAL UTILITY OF GLYCAN-BINDING PROTEINS AND GLYCANS - The present invention relates to the use of glycan-binding polypeptides and glycans as a medicament, in particular for treating and/or preventing helminthic infections or an immune disease. Moreover, the present invention is directed to corresponding pharmaceutical compositions, food products and animal feed comprising isolated glycans and/or glycan-binding polypeptides. In addition, the present invention teaches methods for identifying anti-helminthic carbohydrate-binding polypeptides, for identifying helminthic glycan and gene targets involved in glycan-mediated toxicity, for identifying helminths susceptible to glycan-mediated toxicity, and for identifying anti-helminthic and anti-allergic substances.08-16-2012
20110091437FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.04-21-2011
20120128649MODIFIED NON-CYTOTOXIC PROTEASES - The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.05-24-2012
20120134978Cross-Linking of Superoxide Dismutase Monomers - A stabilized superoxide dismutase (SOD1) analogue, wherein the side chains of two amino acids on two different SOD1 monomers are connected is provided. A method of producing a stabilized superoxide disumutase (SOD1) analogue comprises reacting a first SOD1 monomer, a second SOD1 monomer, and a cross-linker.05-31-2012
20120134977PRODRUGS CONTAINING ALBUMIN BINDING PROBE - The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.05-31-2012
20120213760METHODS AND COMPOSITIONS FOR TREATMENT OF MYOTUBULAR MYOPATHY USING CHIMERIC POLYPEPTIDES COMPRISING MYOTUBULARIN 1(MTM1) POLYPEPTIDES - The present invention provides chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need.08-23-2012
20100047224Biosilica-Adhesive Protein Nanocomposite Materials: Synthesis and Application in Dentistry - The invention concerns the application of silicatein-silk fibroin fusion proteins in dentistry to synthesize silica-containing nanocomposite materials used as filling material.02-25-2010
20120177625CHEMICALLY MODIFIED FACTOR IX - The present invention discloses a chemically modified FIX, wherein the activation peptide region contains a covalently coupled water-soluble hydrophilic polymer.07-12-2012
20120258088CHIMERIC BACTERIOPHAGE LYSIN WITH ACTIVITY AGAINST STAPHYLOCOCCI BACTERIA - The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of 10-11-2012
20120225046VARIANT FORM OF URATE OXIDASE AND USE THEREOF - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.09-06-2012
20120263701COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.10-18-2012
20110123509FUSION MOLECULES OF RATIONALLY-DESIGNED DNA-BINDING PROTEINS AND EFFECTOR DOMAINS - Targeted transcriptional effectors (transcription activators and transcription repressors) derived from meganucleases are described. Also described are nucleic acids encoding same, and methods of using same to regulate gene expression. The targeted transcriptional effectors can comprise (i) a meganuclease DNA-binding domain lacking endonuclease cleavage activity that binds to a target recognition site; and (ii) a transcription effector domain.05-26-2011
20120328590ANTI-CANCER THERAPEUTIC STRATEGY TO OVERCOME CANCER RESISTANCE AND TO ENABLE TAILORING TREATMENT TO PATIENTS - A gene construct comprising a programmed-cell-death executioner gene having a nuclear localization signal, a deleted signal peptide, an inhibitor-resistant binding site, a promoter, and an activator. A method of making a gene construct, by modifying a programmed-cell-death executioner gene by adding a nuclear localization signal, deleting a signal peptide, mutating a binding site for an inhibitor to make it inhibitor-resistant, adding a promoter for exclusive expression in selected cells, and adding an activator. A method of eliminating undesired cells from a patient. A method of treating cancer. An array comprising at least two gene constructs wherein all of the gene constructs differ with respect to the programmed-cell-death executioner gene and the nuclear localization signal. A method of personalizing anti-cancer treatment. A method of increasing DNase 1 resistance to actin binding. A method of increasing catalytic activity of DNase 1 binding.12-27-2012
20120328592STABILIZED ALPHA-GALACTOSIDASE AND USES THEREOF - Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.12-27-2012
20110044967Conjugates Comprising a Biodegradable Polymer and Uses Therefor - Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.02-24-2011
20120321607Factor VII Fusion Polypeptides - The present invention relates to a Factor VII (FVII) fusion polypeptide with a prolonged half-life, wherein the FVII polypeptide can be activated or is in the activated form.12-20-2012
20120321606CRYSTAL STRUCTURES AND METHODS USING SAME - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators.12-20-2012
20120282236METHOD OF DELIVERING OXYGEN USING PEG-HEMOGLOBIN CONJUGATES WITH ENHANCED NITRITE REDUCTASE ACTIVITY - The present invention relates generally to methods for delivering oxygen to tissue and reducing nitrite to nitric oxide in the microvasculature. Specifically, the present invention is directed towards using a deoxygenated pegylated hemoglobin conjugate having enhanced nitrite reductase activity to deliver oxygen to tissues.11-08-2012
20100150896DIAMINOQUINAZOLINE INHIBITORS OF DIHYDROFOLATE REDUCTASE - The present invention relates to new diaminoquinazoline inhibitors of dihydrofolate reductase activity, pharmaceutical compositions thereof, and methods of use thereof.06-17-2010
20120328591METHODS FOR IMPROVING ORAL DELIVERY - The invention provides a method of improving the oral delivery of a therapeutic agent, comprising the step of linking the therapeutic agent to a carrier protein comprising angiogenin, fusion proteins or conjugates comprising angiogenin and a therapeutic agent and their use in medicine.12-27-2012
20120100121Pegylated L-Asparaginase - Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from 04-26-2012
20100183577ENZYME REPLACEMENT THERAPY FOR TREATING LYSOSOMAL STORAGE DISEASES - The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.07-22-2010
20130011378Stable formulations of a hyaluronan-degrading enzyme - Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20).01-10-2013
20130017184Stabilised solid compositions of factor VII polypeptides - The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.01-17-2013
20120148556Formulations for Lysosomal Enzymes - The present invention provides improved formulations for lysosomal enzymes useful for enzyme replacement therapy. Among other things, the present invention provides formulations that preserve or enhance the stability and/or efficacy of a lysosomal enzyme such as acid alpha-glucosidase.06-14-2012
20120148555Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.06-14-2012
20110158973SUPPRESSION OF CANCERS - The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.06-30-2011
20130022588Stable formulations of a hyaluronan-degrading enzyme related applications - Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20).01-24-2013
20110262419SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF - This invention provides chimeric molecules that are catalytic antagonists of a target molecule. The catalytic antagonists of this invention preferably comprise a targeting moiety attached to an enzyme that degrades the molecule specifically bound by the targeting moiety. The catalytic antagonists of this invention thus bind to a target recognized by the targeting moiety (e.g., a receptor) the enzyme component of the chimera then degrades all or part of the target. This typically results in a reduction or loss of activity of the target and release of the chimeric molecule. The chimeric molecule is then free to attack and degrade another target molecule.10-27-2011
20130171122ENDOPEPTIDASE AND NEUROTOXIN COMBINATION TREATMENT OF BLADDER DISORDERS - The present specification discloses Clostridial neurotoxins and TEMs, compositions comprising such Clostridial neurotoxins and TEMs, kits comprising such Clostridial neurotoxins, TEMs and/or compositions, methods of treating a bladder disorder in an individual using such Clostridial neurotoxins, TEMs and/or compositions, use of such Clostridial neurotoxins and TEMs in manufacturing a medicament for treating a bladder disorder, and uses of such Clostridial neurotoxins, TEMs and/or compositions in treating a bladder disorder.07-04-2013
20130142771STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES - A hydrolytic enzyme is stabilized in a liquid surfactant preparation using a component that stabilizes the hydrolytic enzyme and encompasses an oligoaminobiphenyl oligocarboxylic acid.06-06-2013
20130142772STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES - A hydrolytic enzyme is stabilized in a liquid surfactant preparation using a component that stabilizes the hydrolytic enzyme and includes a phenylalkyldicarboxylic acid.06-06-2013
20130177545METHODS FOR INTRODUCING MANNOSE 6 PHOSPHATE AND OTHER OLIGOSACCHARIDES ONTO GLYCOPROTEINS AND APPLICATIONS THEREOF - Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.07-11-2013
20130129700FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.05-23-2013
20130101570SERINE PROTEASE DERIVATIVES AND USES IN THE PREVENTION OR THE TREATMENT OF BLOOD COAGULATION DISORDERS - The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.04-25-2013
20130149293STABLE COMPOSITIONS OF FACTOR IX - The invention allows substantial improvements in stability of coagulation Factor IX in aqueous compositions. An aqueous composition sealed in a non-glass container comprising Factor IX in a buffer and calcium ions is provided, together with methods of stabilizing an aqueous Factor IX composition comprising storing said composition in a non-glass container for at least 7 days.06-13-2013
20130156747PEGylated Mutated Clostridium botulinum Toxin - The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C)06-20-2013
20130183280STABILIZED FACTOR VIII VARIANTS - The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.07-18-2013
20130183279Fibrin Formulations for Wound Healing - Fibrin formulations, fibrin matrices and kits for wound healing, use of the formulation, matrices and foams, and kits and methods of using thereof, are described herein. In a preferred aspect, the compositions are suitable for use for local administration. In another preferred aspect, the compositions are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices and foams.07-18-2013
20110311505Photosensitive Aminoacid-Monomer Linkage and Bioconjugation Applications in Life Sciences and Biotechnology - This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation. The photosensitive conjugation based on click biochemistry can be carried out at mild conditions, independent of pH and temperature, without affecting conformation and function of protein.12-22-2011
20130189239Conjugated Factor VIII Molecules - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.07-25-2013
20120003201VAULT AGENTS FOR CHRONIC KIDNEY DISEASE - The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.01-05-2012
20120027743Method for the Treatment of Hemophilia - The present invention is directed to a method for the treatment of hemophilia.02-02-2012
20120027742METHODS FOR TREATING ADULT RESPIRATORY DISTRESS SYNDROME - We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.02-02-2012
20130195829Themostable Phytase Variants - The present invention relates to a method for producing phytase variants which has at least 74% identity to a phytase derived from 08-01-2013
20120034202AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I):02-09-2012
20120301454Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.11-29-2012
20120093795COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies.04-19-2012
20120093794Methods for Treating Pompe Disease - The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner.04-19-2012

Patent applications in class Stabilized enzymes or enzymes complexed with nonenzyme (e.g., liposomes, etc.)